Related Experiment Video

Updated: Jan 17, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K

Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC

Barbara Melosky1, Quincy S C Chu2, Rosalyn A Juergens3

  • 1British Columbia Cancer Agency, Vancouver Centre, 600 10th Ave W, Vancouver, BC V5Z 4E6, Canada.

Lung Cancer (Amsterdam, Netherlands)
|September 18, 2025
PubMed

Insights

Updated Canadian guidelines recommend upfront anaplastic lymphoma kinase (ALK) testing and next-generation ALK inhibitors for advanced non-small cell lung carcinoma (NSCLC) patients. High-risk resected patients should receive adjuvant alectinib.

Area of Science:

  • Oncology
  • Thoracic Medicine
  • Genomic Medicine

Background:

  • Anaplastic lymphoma kinase (ALK) inhibition improves survival in advanced non-small cell lung carcinoma (NSCLC).
  • Previous Canadian consensus (2016, 2018) recommended first- and second-generation ALK inhibitors for advanced ALK-rearranged NSCLC.
  • New scientific literature necessitates an update to these recommendations.

Purpose of the Study:

  • To review pivotal and phase III ALK inhibitor trials.
  • To assess benefits, risks, and implications of new data relative to current Canadian guidance for ALK-rearranged NSCLC.
  • To provide updated consensus recommendations for Canadian ALK-rearranged NSCLC management.

Main Methods:

  • Review of ALK inhibitor pivotal and phase III clinical trials.
  • Assessment of benefits, risks, and implications for Canadian clinical practice.
  • Development of updated consensus recommendations based on current evidence.

Main Results:

  • Strong support for upfront anaplastic lymphoma kinase (ALK) testing in non-small cell lung carcinoma (NSCLC).
  • Recommendation for adjuvant alectinib treatment for high-risk resected patients.
  • Endorsement of next-generation ALK inhibitors (lorlatinib, alectinib, brigatinib) as initial treatment for advanced ALK-rearranged NSCLC.

Conclusions:

  • Major developments in ALK-rearranged NSCLC management are relevant to the Canadian context.
  • Updated recommendations emphasize early ALK testing and advanced treatment strategies.
  • Next-generation ALK inhibitors represent a significant advancement in treating ALK-rearranged NSCLC.
Keywords:
ALK inhibitorsALK rearrangementCNS metastasesConsensusNon-small cell lung cancerTyrosine kinase inhibitors

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.1K
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K